卓勝微(300782.SZ)目前自產的射頻開關產品在客戶端逐步放量提升,已覆蓋多家品牌客戶以及絕大部分 ODM 客戶
格隆匯3月5日丨卓勝微(300782.SZ)在投資者互動平臺表示,公司產線建設順利,12 英寸 IPD 平臺已正式進入規模量產階段,L-PAMiF、LFEM 等相關模組產品中採用自產 IPD 濾波器的比例已達到較高水平。12 英寸射頻開關和低噪聲放大器的第一代工藝生產線已實現工藝通線進入量產階段,逐步形成產出和產能爬坡。目前自產的射頻開關產品在客戶端逐步放量提升,已覆蓋多家品牌客戶以及絕大部分 ODM 客戶。 與此同時,射頻開關產品在2024年三季度已集成至模組開始量產出貨。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.